Roberts L R, Kamath P S
Division of Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clin Proc. 1996 Sep;71(9):874-81. doi: 10.4065/71.9.874.
Ascites, a late manifestation of cirrhosis of the liver, causes increased morbidity and mortality. The renin-angiotensin-aldosterone system, the sympathetic nervous system, and arginine vasopressin are responsible for sodium and water retention in patients with cirrhosis. Fluid localizes to the peritoneal cavity mainly as a result of portal hypertension. Recent developments in the understanding of the pathophysiologic mechanisms of ascites include the role of inadequate renal prostaglandin production in the development of the hepatorenal syndrome and the possible role of nitric oxide in the pathogenesis of the renal complications of cirrhosis. The aim of medical therapy is to achieve a negative sodium balance and, consequently, fluid loss. Large-volume paracentesis is safe and effective in the management of tense ascites, but use of diuretic agents should be continued to prevent reaccumulation of ascites. Liver transplantation, transjugular intrahepatic portosystemic shunts, or LeVeen shunts should be considered in selected patients with persistent ascites. In patients with diuretic-resistant or diuretic-refractory ascites, a thorough assessment must be performed to exclude potentially reversible causes. The hepatorenal syndrome has an associated grave prognosis, especially in patients who are not candidates for liver transplantation.
腹水是肝硬化的晚期表现,会增加发病率和死亡率。肾素 - 血管紧张素 - 醛固酮系统、交感神经系统和精氨酸加压素是肝硬化患者钠水潴留的原因。液体主要由于门静脉高压而积聚在腹腔。对腹水病理生理机制理解的最新进展包括肾前列腺素生成不足在肝肾综合征发生中的作用以及一氧化氮在肝硬化肾脏并发症发病机制中的可能作用。药物治疗的目的是实现负钠平衡,从而实现液体丢失。大量腹腔穿刺放液在治疗张力性腹水方面安全有效,但应继续使用利尿剂以防止腹水再次积聚。对于持续腹水的特定患者,应考虑肝移植、经颈静脉肝内门体分流术或LeVeen分流术。对于利尿剂抵抗或难治性腹水患者,必须进行全面评估以排除潜在的可逆性病因。肝肾综合征预后严重,尤其是对于不适合肝移植的患者。